Newron Pharmaceuticals S.p.A. | WebDisclosure

Basculer en Français

10374	Companies
216189	Keywords
145889	Articles
114464	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

PRESS RELEASE

published on 04/08/2024 at 07:00, 2 years 1 month ago

Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
Newron Pharmaceuticals presented data from study 014/015 and evenamide clinical development outlook at SIRS 2024 Congress, showcasing potential for new TRS treatment options

Clinical Development Newron Pharmaceuticals Evenamide Study 014/015 Schizophrenia International Research Society
BRIEF

published on 03/19/2024 at 07:05, 2 years 1 month ago

Newron Pharmaceuticals S.p.A. Announces 2023 Financial Results and Provides Outlook for 2024

2024 Outlook Financial Results 2023 Newron Pharmaceuticals Evenamide Development Xadago Safinamide
BRIEF

published on 03/19/2024 at 07:05, 2 years 1 month ago

Newron Pharmaceuticals SpA annonce ses résultats financiers pour 2023 et fournit des perspectives pour 2024

Perspectives 2024 Résultats Financiers 2023 Produits Pharmaceutiques Newron Xadago Safinamide Développement D'Evenamide
PRESS RELEASE

published on 03/19/2024 at 07:00, 2 years 1 month ago

Newron presents 2023 financial results and provides 2024 outlook
Newron Pharmaceuticals S.p.A. presents 2023 financial results and 2024 outlook, including advancements in schizophrenia treatment and strategic partnerships

Financial Results 2024 Outlook Partnerships Newron Pharmaceuticals Schizophrenia Treatment
BRIEF

published on 03/15/2024 at 07:05, 2 years 1 month ago

Newron Pharmaceuticals S.p.A. Announces Amended Repayment Agreement with European Investment Bank

European Investment Bank Newron Pharmaceuticals Financing Agreement Evenamide CNS Treatments
BRIEF

published on 03/15/2024 at 07:05, 2 years 1 month ago

Newron Pharmaceuticals SpA annonce un accord de remboursement modifié avec la Banque européenne d'investissement

Produits Pharmaceutiques Newron Evenamide Banque Européenne D'investissement Accord De Financement Traitements Du SNC
PRESS RELEASE

published on 03/15/2024 at 07:00, 2 years 1 month ago

Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
Newron Pharmaceuticals S.p.A. agrees with EIB to extend repayment dates of 2018 financing agreement tranches after pipeline milestones

European Investment Bank Financing Agreement Evenamide Newron Pharmaceuticals S.p.A. Loan Repayment Dates
BRIEF

published on 03/14/2024 at 18:37, 2 years 1 month ago

Newron Pharmaceuticals Secures Up to EUR 15 Million in Funding Through New Share Issuance

Share Issuance Biopharmaceuticals Investment Agreement Newron Pharmaceuticals CNS Therapies
BRIEF

published on 03/14/2024 at 18:37, 2 years 1 month ago

Newron Pharmaceuticals obtient jusqu'à 15 millions d'euros de financement grâce à l'émission de nouvelles actions

Émission D'actions Produits Biopharmaceutiques Accord D'investissement Produits Pharmaceutiques Newron Thérapies Du SNC
PRESS RELEASE

published on 03/14/2024 at 18:32, 2 years 1 month ago

Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million
Newron Pharmaceuticals S.p.A. enters a subscription agreement for up to 2.05 million new shares, aiming to raise EUR 15.0 million. The investment supports CNS therapies development

Subscription Agreement Newron Pharmaceuticals Newly Issued Shares EUR 15.0 Million CNS Therapies Development

Accesswire

Published on 05/09/2026 at 01:55, 2 days 5 hours ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 2 days 5 hours ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 2 days 5 hours ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 2 days 7 hours ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 2 days 7 hours ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 05/11/2026 at 06:55, 5 minutes ago

STRATEC POSTS RESULTS FOR THE FIRST QUARTER OF 2026
Published on 05/10/2026 at 16:05, 14 hours 55 minutes ago

RingConn Gen 3 Smart Ring Opens for Pre-Order: Bringing Vascular Insights to Effortless Everyday Wear
Published on 05/10/2026 at 14:00, 17 hours ago

MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Published on 05/10/2026 at 11:45, 19 hours 15 minutes ago

Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Published on 05/09/2026 at 19:05, 1 day 11 hours ago

LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency

Les Echos

Published on 05/07/2026 at 19:15, 3 days 11 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 3 days 11 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 3 days 11 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 3 days 11 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 3 days 12 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE